News
Meta-analysis of the Effectiveness of Romosozumab in the Treatment of Postmenopausal Osteoporosis
Osteoporosis is a prevalent disease with unmet therapeutic needs. Whether the anti-sclerostin antibody romosozumab can offer an effective improvement in osteoporosis treatment outcomes in postmenopausal women was the central question addressed by the meta-analysis presented below.
Lurasidone in a Patient with Paranoid Schizophrenia and Asperger's Syndrome – A Case Study
Lurasidone is an effective and very gentle antipsychotic which is establishing a prominent position…
Clinical Significance of Smaller Gaps Between Strengths of Levothyroxine Preparations in the Treatment of Hypothyroidism
Many levothyroxine preparations have relatively large intervals between doses (25 µg, 50 µg, and 75…
Generic Substitution of Levothyroxine in Practice
The active ingredient levothyroxine is found in a significant number of medicinal products (MP) in…
Options for Systemic Therapy of Advanced Stage Small Cell Lung Cancer
Small cell lung cancer (SCLC) is the most aggressive type of lung tumor. Although it responds well…
Current Sequence of Treatment for Metastatic HER2+ Breast Cancer
In September 2023, experts from Miami Cancer Institute published their consensus statement on the…
Artificial Intelligence and Deep Learning as the Future of Glaucoma Diagnosis
Glaucoma represents a group of eye diseases characterized by changes to the optic nerve. It is the…
MUDr. Jana Zárubová: Experiences with buccal midazolam in real practice are positive and we can significantly improve patients' quality of life
Recently, it has emerged as an alternative to traditionally rectally administered diazepam for…
IEC 2023: Key Challenges for Epilepsy Patients Include Status Epilepticus and Anxiety Management
Why is anxiety a significant issue for epilepsy patients? What do current insights say about the…
Ocrelizumab in the Treatment of Multiple Sclerosis – 10-Year Data
Multiple sclerosis (MS) is a lifelong disease with a high risk of permanent disability. Current…